Page last updated: 2024-11-13

am4113

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AM4113: a cannabinoid CB1 receptor neutral antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66844170
SCHEMBL ID922969
MeSH IDM0522635

Synonyms (21)

Synonym
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide ,
BBUKVPCUOHFAQN-UHFFFAOYSA-N ,
5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1h-pyrazole-3-carboxylic acid amide
(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide
SCHEMBL922969
unii-bbw5x7964a
am 4113
am4113, >=98% (hplc)
1h-pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
BBW5X7964A ,
614726-85-1
am-4113
AKOS032962878
am4113
cb1 antagonist 2
HY-116649
CS-0066157
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide
DTXSID301027454
AS-84165

Research Excerpts

Treatment

AM4113 pretreatment reduced ethanol-induced increase in dopamine release in nucleus accumbens. The AM4113 treated group had 29.3±11.4% lower fat mass than vehicle-treated rats. Treatment also increased the mRNA levels of Creb1 and Cbp in the amygdala.

ExcerptReferenceRelevance
"AM4113 pretreatment reduced ethanol-induced increase in dopamine release in nucleus accumbens."( Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.
Balla, A; Dong, B; Makriyannis, A; Pandey, SC; Sershen, H; Shilpa, BM; Suckow, RF; Vemuri, K; Vinod, KY, 2018
)
1.2
"The AM4113 treated group had 29.3±11.4% lower fat mass than vehicle-treated rats; this trend did not reach statistical significance."( The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.
Chambers, AP; Cluny, NL; Eller, LK; Freni, C; Makriyannis, A; Reimer, RA; Sharkey, KA; Vemuri, VK; Wood, JT, 2011
)
1.11
"Treatment with AM4113 also increased the mRNA levels of Creb1 and Cbp in the amygdala as well as the protein levels of pCREB, CBP, H3K9ac and H3K14ac in the central and medial nucleus of amygdala, but not in the basolateral amygdala."( CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking.
Banerjee, R; Dong, B; Dulman, RS; Hungund, BL; Krishnan, HR; Pandey, SC; Vinod, KY; Zhang, H, 2021
)
0.96

Dosage Studied

ExcerptRelevanceReference
" To further investigate the specificity of effects on partner preference, we repeated our URB597 dosing regimen on an additional group of females and tested their anxiety-related behavior in both an elevated-plus maze and a light/dark test."( Effects of systemic endocannabinoid manipulation on social and exploratory behavior in prairie voles (Microtus ochrogaster).
Bales, KL; Simmons, TC; Singh, ALK, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (25.00)29.6817
2010's16 (57.14)24.3611
2020's5 (17.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.77 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index3.44 (0.95)

This Compound (21.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]